Literature DB >> 10448907

Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy.

S Ghatpande1, S Goswami, E Mascareno, M A Siddiqui.   

Abstract

In comparing the pathological state of cardiac hypertrophy with early embryonic growth and development of the primitive heart, important and informative aspects of mechanisms that underlie activation of the gene expression pattern become apparent. Interestingly, in both cases the muscle phenotypes share the expression of a 'fetal' gene expression program, raising the question whether the same genetic mechanism is being called upon by signals associated with the onsets of cardiogenesis and myocardial hypertrophy. A cell specific transcription factor, CLP-1, was recently identified in our laboratory that is likely to play a crucial role, in conjunction with other known regulatory factors, in early cardiac events leading to cardiogenic cell specification and differentiation. We have also identified a novel mechanism that involves activation of the Jak/Stat signaling pathway that is linked to the autocrine angiotensin-II loop associated with the hypertrophic response in cardiomyocytes. Since early cardiac cell development and the hypertrophic state involve the expression of the same battery of genes, one may speculate that common transcription factors may account for assembling a competent apparatus responsible for transcribing the genes. Our present studies are designed to investigate the potential role of these factors in control of both processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448907

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  47 in total

Review 1.  Pattern formation during animal development.

Authors:  D A Melton
Journal:  Science       Date:  1991-04-12       Impact factor: 47.728

Review 2.  NK-2 homeobox genes and heart development.

Authors:  R P Harvey
Journal:  Dev Biol       Date:  1996-09-15       Impact factor: 3.582

3.  Marginal zone cells--the primitive streak-inducing component of the primary hypoblast in the chick.

Authors:  Y Azar; H Eyal-Giladi
Journal:  J Embryol Exp Morphol       Date:  1979-08

Review 4.  Signaling pathways in cardiac myocyte hypertrophy.

Authors:  M A Hefti; B A Harder; H M Eppenberger; M C Schaub
Journal:  J Mol Cell Cardiol       Date:  1997-11       Impact factor: 5.000

5.  Antithetical accumulation of myosin heavy chain but not alpha-actin mRNA isoforms during early stages of pressure-overload-induced rat cardiac hypertrophy.

Authors:  C Chassagne; C Wisnewsky; K Schwartz
Journal:  Circ Res       Date:  1993-04       Impact factor: 17.367

6.  The Xenopus GATA-4/5/6 genes are associated with cardiac specification and can regulate cardiac-specific transcription during embryogenesis.

Authors:  Y Jiang; T Evans
Journal:  Dev Biol       Date:  1996-03-15       Impact factor: 3.582

7.  Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5.

Authors:  I Lyons; L M Parsons; L Hartley; R Li; J E Andrews; L Robb; R P Harvey
Journal:  Genes Dev       Date:  1995-07-01       Impact factor: 11.361

Review 8.  Control of cardiac gene transcription by fibroblast growth factors.

Authors:  M D Schneider; L A Kirshenbaum; T Brand; W R MacLellan
Journal:  Mol Reprod Dev       Date:  1994-09       Impact factor: 2.609

9.  Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor.

Authors:  C Grépin; G Nemer; M Nemer
Journal:  Development       Date:  1997-06       Impact factor: 6.868

10.  Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis.

Authors:  D G Edmondson; G E Lyons; J F Martin; E N Olson
Journal:  Development       Date:  1994-05       Impact factor: 6.868

View more
  7 in total

1.  Evidence for calreticulin attenuation of cardiac hypertrophy induced by pressure overload and soluble agonists.

Authors:  Sylvia Papp; Ewa Dziak; Golam Kabir; Peter Backx; Sophie Clement; Michal Opas
Journal:  Am J Pathol       Date:  2010-01-28       Impact factor: 4.307

2.  Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin.

Authors:  David S Paul; Trisha J Grevengoed; Florencia Pascual; Jessica M Ellis; Monte S Willis; Rosalind A Coleman
Journal:  Biochim Biophys Acta       Date:  2014-03-12

3.  Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.

Authors:  Ayumi Takakura; Erik A Nelson; Nadeem Haque; Benjamin D Humphreys; Kambiz Zandi-Nejad; David A Frank; Jing Zhou
Journal:  Hum Mol Genet       Date:  2011-08-05       Impact factor: 6.150

4.  Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy.

Authors:  Jessica M Ellis; Shannon M Mentock; Michael A Depetrillo; Timothy R Koves; Shiraj Sen; Steven M Watkins; Deborah M Muoio; Gary W Cline; Heinrich Taegtmeyer; Gerald I Shulman; Monte S Willis; Rosalind A Coleman
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

5.  Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1.

Authors:  Jorge Espinoza-Derout; Michael Wagner; Louis Salciccioli; Jason M Lazar; Sikha Bhaduri; Eduardo Mascareno; Brahim Chaqour; M A Q Siddiqui
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

6.  Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy.

Authors:  Hong Yue; Wei Li; Russell Desnoyer; Sadashiva S Karnik
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

7.  Temporal patterns of tyrosine nitration in embryo heart development.

Authors:  Liliana Viera; Milka Radmilovich; Marcelo R Vargas; Cassandra N Dennys; Landon Wilson; Stephen Barnes; Maria Clara Franco; Joseph S Beckman; Alvaro G Estévez
Journal:  Free Radic Biol Med       Date:  2012-11-27       Impact factor: 7.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.